Oren M Becker

Summary

Publications

  1. ncbi Modeling the 3D structure of GPCRs: advances and application to drug discovery
    Oren M Becker
    Predix Pharmaceuticals Ltd, SAP Building, 3 Hayetzira Street, Ramat Gan 52521, Israel
    Curr Opin Drug Discov Devel 6:353-61. 2003
  2. ncbi G protein-coupled receptors: in silico drug discovery in 3D
    Oren M Becker
    Predix Pharmaceuticals, Ltd, S A P Building, 3 Hayetzira Street, Ramat Gan 52521, Israel
    Proc Natl Acad Sci U S A 101:11304-9. 2004
  3. ncbi An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression
    Oren M Becker
    Predix Pharmaceuticals Ltd, 3 Hayetzira Street, Ramat Gan 52521, Israel
    J Med Chem 49:3116-35. 2006
  4. ncbi PREDICT modeling and in-silico screening for G-protein coupled receptors
    Sharon Shacham
    Predix Pharmaceuticals Ltd, Ramat Gan, Israel
    Proteins 57:51-86. 2004
  5. ncbi NO rebinding to myoglobin: a reactive molecular dynamics study
    Markus Meuwly
    Laboratoire de Chimie Biophysique, ISIS UMR 7006, Universite Louis Pasteur, 67000, Strasbourg, France
    Biophys Chem 98:183-207. 2002

Collaborators

  • Maya Topf
  • Shay Bar-Haim
  • Martin Karplus
  • Sharon Shacham
  • Markus Meuwly
  • Alexander Heifetz
  • Noa Avisar
  • Ori Kalid
  • Yael Marantz
  • Dora Warshaviak
  • Silvia Noiman
  • Zvi Naor
  • Merav Fichman
  • Boaz Inbal
  • Roland Stote

Detail Information

Publications5

  1. ncbi Modeling the 3D structure of GPCRs: advances and application to drug discovery
    Oren M Becker
    Predix Pharmaceuticals Ltd, SAP Building, 3 Hayetzira Street, Ramat Gan 52521, Israel
    Curr Opin Drug Discov Devel 6:353-61. 2003
    ..Thus, 3D models of GPCRs should now allow the use of productive structure-based approaches for drug discovery...
  2. ncbi G protein-coupled receptors: in silico drug discovery in 3D
    Oren M Becker
    Predix Pharmaceuticals, Ltd, S A P Building, 3 Hayetzira Street, Ramat Gan 52521, Israel
    Proc Natl Acad Sci U S A 101:11304-9. 2004
    ..These assays validated the quality of the hits as lead compounds for drug discovery. The results demonstrate the usefulness and robustness of ab initio in silico 3D models and of in silico screening for GPCR drug discovery...
  3. ncbi An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression
    Oren M Becker
    Predix Pharmaceuticals Ltd, 3 Hayetzira Street, Ramat Gan 52521, Israel
    J Med Chem 49:3116-35. 2006
    ..We believe that this is one of the first examples for a Phase III drug candidate that was discovered and optimized, from start to finish, using in silico model-based methods as the primary tool...
  4. ncbi PREDICT modeling and in-silico screening for G-protein coupled receptors
    Sharon Shacham
    Predix Pharmaceuticals Ltd, Ramat Gan, Israel
    Proteins 57:51-86. 2004
    ..Namely, the PREDICT models can be used to identify active small-molecule ligands embedded in large compound libraries with an efficiency comparable to that obtained using crystal structures for non-GPCR targets...
  5. ncbi NO rebinding to myoglobin: a reactive molecular dynamics study
    Markus Meuwly
    Laboratoire de Chimie Biophysique, ISIS UMR 7006, Universite Louis Pasteur, 67000, Strasbourg, France
    Biophys Chem 98:183-207. 2002
    ..This effect is due mainly to protein relaxation and may contribute to the experimentally observed non-exponential rebinding rate of NO, as has been suggested previously...